Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Third party research

Orexo: Sales came in better than expected - Nordea

Orexo

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Orexo reported its Q2 numbers this morning with sales of SEK 142.8, 2.1% ahead of our expectations (SEK139.9) and down 20% from last year (SEK 179.1m). EBITDA was -41.1 (38% more negative than we expected) and the reported opex was SEK -178m (-12% vs our estimates). Sales of Zubsolv came in at SEK 126m, a decline of 30% y/y and 4.5% below our forecast. The spending increase is attributable to improved R&D expenses related to OX124 and digital therapies. The financial outlook is unchanged. Deviation table below.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team